论文部分内容阅读
目的:观察七味白术散加减配合西药治疗糖尿病肾病的临床疗效。方法:采用随机平行对照研究,将53例住院患者按病历号抽签随机分为两组。对照组26例予雷米普利联合胰激肽原酶片治疗,治疗组27例在对照组治疗基础上合用七味白术散治疗,观察两组的临床疗效及不良反应。结果:治疗组中显效15例、有效10例、无效2例,总有效率为92.59%;对照组中显效9例、有效8例、无效9例,总有效率为65.38%。两组比较差异有统计学意义(P<0.05)。治疗组不良反应发生率为11.11%,对照组出现恶心1例、视力模糊2例、头晕2例,不良反应总发生率为19.23%。两组比较差异无统计学意义(P>0.05)。结论:七味白术散加减配合西药治疗糖尿病肾病疗效显著,安全性高。
Objective: To observe the clinical curative effect of Qiwei Baizhu San combined with western medicine on diabetic nephropathy. Methods: Randomized controlled trials were conducted in which 53 inpatients were randomly divided into two groups according to their medical records. In the control group, 26 patients were treated with ramipril combined with pancreatic kallikrein, and 27 patients in the treatment group were treated with the combination of Qiweibaizhu San. The clinical efficacy and adverse reactions of the two groups were observed. Results: In the treatment group, 15 cases were markedly effective, 10 cases were effective and 2 cases were ineffective. The total effective rate was 92.59%. In the control group, 9 cases were markedly effective, 8 cases were effective and 9 cases were ineffective. The total effective rate was 65.38%. The difference between the two groups was statistically significant (P <0.05). The incidence of adverse reactions in the treatment group was 11.11%. In the control group, nausea occurred in 1 case, blurred vision in 2 cases and dizziness in 2 cases. The total incidence of adverse reactions was 19.23%. There was no significant difference between the two groups (P> 0.05). Conclusion: Qiweibaizhu San plus western medicine treatment of diabetic nephropathy significant effect, high safety.